Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-13

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

NCT03158090

Acromegaly

RECRUITING

Cardiovascular Outcome After Surgery or Somatostatin Analogues

NCT00615004

Acromegaly

COMPLETED

Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery

NCT00500227

Acromegaly

COMPLETED

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

NCT05431803

Acromegaly

COMPLETED

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

NCT00517491

Acromegaly

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acromegaly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient cohort

No interventions assigned to this group

Physician cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For Patients:

* Age 18 years or older
* Diagnosed with acromegaly
* Receiving current SSA injections for acromegaly treatment for at least 3 months
* Signed electronic Informed Consent Form (eICF)

For Physicians:

* Licensed endocrinologists or neurosurgeons
* Having prescribed SSAs for at least five patients with acromegaly in the past 6 months
* Signed eICF

Exclusion Criteria

* Patients will not be included in the survey if they meet any of the following criteria:
* Patients who are not able to successfully complete the questionnaire independently
* Pregnant patients

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No